NO20083026L - Terapeutisk middel for diabetes - Google Patents

Terapeutisk middel for diabetes

Info

Publication number
NO20083026L
NO20083026L NO20083026A NO20083026A NO20083026L NO 20083026 L NO20083026 L NO 20083026L NO 20083026 A NO20083026 A NO 20083026A NO 20083026 A NO20083026 A NO 20083026A NO 20083026 L NO20083026 L NO 20083026L
Authority
NO
Norway
Prior art keywords
diabetes
therapeutic agent
symbol
salt
formula
Prior art date
Application number
NO20083026A
Other languages
English (en)
Norwegian (no)
Inventor
Hajime Takashima
Koji Takeuchi
Yusuke Moritoh
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20083026L publication Critical patent/NO20083026L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20083026A 2005-12-28 2008-07-04 Terapeutisk middel for diabetes NO20083026L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005379407 2005-12-28
JP2006061722 2006-03-07
PCT/JP2006/326141 WO2007074884A1 (fr) 2005-12-28 2006-12-27 Agent thérapeutique pour traiter le diabète

Publications (1)

Publication Number Publication Date
NO20083026L true NO20083026L (no) 2008-09-16

Family

ID=38218106

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083026A NO20083026L (no) 2005-12-28 2008-07-04 Terapeutisk middel for diabetes

Country Status (16)

Country Link
US (1) US20090042863A1 (fr)
EP (1) EP1970063A4 (fr)
JP (1) JP5094416B2 (fr)
KR (1) KR20080081354A (fr)
AU (1) AU2006330332B2 (fr)
BR (1) BRPI0620718A2 (fr)
CA (1) CA2635777A1 (fr)
GE (1) GEP20105033B (fr)
IL (1) IL192369A0 (fr)
MA (1) MA30176B1 (fr)
ME (1) MEP7609A (fr)
MY (1) MY152172A (fr)
NO (1) NO20083026L (fr)
NZ (1) NZ569661A (fr)
RU (1) RU2438671C2 (fr)
WO (1) WO2007074884A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95828C2 (ru) * 2007-02-01 2011-09-12 Такеда Фармасьютикал Компани Лимитед Твердая рецептура, которая содержит алоглиптин и пиоглитазон
EP2185138B1 (fr) * 2007-07-19 2016-09-07 Takeda Pharmaceutical Company Limited Preparation solide comprenant du alogliptin et metformin chlorhydrate
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
KR101607081B1 (ko) * 2008-05-14 2016-03-29 가부시키가이샤산와카가쿠켄큐쇼 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009281122C1 (en) 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
KR101054911B1 (ko) 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
EP2379522B1 (fr) * 2008-12-23 2018-02-28 Sandoz AG Forme cristalline d'alogliptine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011079778A1 (fr) 2009-12-30 2011-07-07 China Shanghai Fochon Pharmaceutical Co Ltd Dérivés de 3-(3-aminopipéridin-1-yl)-5-oxo-1,2,4-triazine à titre d'inhibiteurs de dipeptidyl peptidase iv (dpp-iv)
EP2547339A1 (fr) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
EA027324B1 (ru) 2011-11-11 2017-07-31 Пфайзер Инк. 2-тиопиримидиноны
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
PE20180503A1 (es) 2015-05-05 2018-03-09 Pfizer 2-tiopirimidinonas

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
EP0862562B1 (fr) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Composes de benzoxazepine, leur production et leur utilisation en tant qu'agent d'abaissement des niveaux de lipides
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2386517A1 (fr) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Derives d'amines
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
DK1228067T3 (da) 1999-11-10 2004-12-06 Takeda Chemical Industries Ltd 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning
BRPI0107715B8 (pt) * 2000-01-21 2021-05-25 Novartis Ag produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
DK1285651T3 (da) 2000-04-28 2010-12-13 Takeda Pharmaceutical Melanin-koncentrerende hormon-antagonister
EP1283199A4 (fr) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd Antagoniste de l'hormone de concentration de la melanine
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003042204A1 (fr) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Derive d'amine
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
BRPI0413452A (pt) * 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070259927A1 (en) * 2004-08-26 2007-11-08 Takeda Pharmaceutical Company Limited Remedy for Diabetes
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
MY152172A (en) 2014-08-15
WO2007074884A1 (fr) 2007-07-05
BRPI0620718A2 (pt) 2011-11-22
IL192369A0 (en) 2011-08-01
AU2006330332B2 (en) 2012-03-08
RU2008130878A (ru) 2010-02-10
CA2635777A1 (fr) 2007-07-05
KR20080081354A (ko) 2008-09-09
NZ569661A (en) 2011-06-30
EP1970063A4 (fr) 2014-05-21
RU2438671C2 (ru) 2012-01-10
US20090042863A1 (en) 2009-02-12
GEP20105033B (en) 2010-06-25
JPWO2007074884A1 (ja) 2009-06-04
MA30176B1 (fr) 2009-01-02
JP5094416B2 (ja) 2012-12-12
AU2006330332A1 (en) 2007-07-05
MEP7609A (en) 2011-12-20
EP1970063A1 (fr) 2008-09-17

Similar Documents

Publication Publication Date Title
NO20083026L (no) Terapeutisk middel for diabetes
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
NO20081196L (no) Terapeutisk middel for diabetes
BRPI0507198A (pt) derivados de bisariluréia
MX2010009736A (es) Compuesto heterociclico.
TNSN06030A1 (en) Substituted thiazole-benzoisothiazole dioxide derivavites, method for the production thereof and use of the same
MX2008000255A (es) Activadores de urea glucocinasa.
GEP20146060B (en) Pyridyl inhibitors of hedgehog signalling
MY149622A (en) Pyrazoles as 11-beta-hsd-1
BRPI0509573A (pt) derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
NO20085056L (no) Insulinderivat
GEP20115359B (en) Fused cyclic compounds
MX2009009417A (es) Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
NO20074872L (no) Pyrazoler
DK1973541T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater til nedsættelse af lipid- og blodglucoseniveauer
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application